Towa Pharmaceutical Co Ltd 2025 IR
The report outlines Towa Pharmaceutical's strategic initiatives and performance for the fiscal year 2024. Key highlights include the expansion of the Yamagata Plant's production capacity to achieve an annual target of 17.5 billion tablets by FY2026, addressing the generic drug shortage in Japan. The company also advanced its sustainability management, aligning with TCFD recommendations and achieving a B score in CDP's climate change questionnaire. Additionally, Towa launched Japan's first twice-weekly Alzheimer's treatment patch and initiated clinical trials for drug repurposing.
Company: Towa Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2025
Type: IR
Pages: 62
Towa Pharmaceutical Co Ltd
Integrated Report
The report outlines Towa Pharmaceutical's strategic initiatives and performance for the fiscal year 2024. Key highlights include the expansion of the Yamagata Plant's production capacity to achieve an annual target of 17.5 billion tablets by FY2026, addressing the generic drug shortage in Japan. The company also advanced its sustainability management, aligning with TCFD recommendations and achieving a B score in CDP's climate change questionnaire. Additionally, Towa launched Japan's first twice-weekly Alzheimer's treatment patch and initiated clinical trials for drug repurposing.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women in Management
Net Zero Target
Employees